Welcome to our dedicated page for Longevity Health news (Ticker: XAGEW), a resource for investors and traders seeking the latest updates and insights on Longevity Health stock.
Longevity Health Holdings, Inc., whose warrants trade under the symbol XAGEW, generates news around its focus on human longevity and healthy aging. Company announcements emphasize regenerative bio-aesthetics, diagnostics, and nutrition, along with capital markets developments and merger activity. For readers tracking XAGEW-related updates, these disclosures provide insight into both the company’s product focus and its corporate actions.
News releases describe Longevity Health Holdings’ bio-aesthetic technologies, including Carmell Secretome™ and Elevai Exosomes™, aimed at skin and hair health. They also outline a strategy to expand in diagnostics for early detection and proactive management of chronic disease risk, highlighted by a merger agreement with 20/20 BioLabs, Inc., which offers tests such as the OneTest™ multi-cancer early detection blood test and an expected longevity-oriented inflammatory biomarker test.
Corporate transaction news has included the acquisition of Carmell Therapeutics and Elevai Skincare, the execution of a merger agreement with 20/20 BioLabs, and a later merger agreement with True Health Inc., which operates plasma collection centers under the THPlasma brand. Subsequent filings report that the True Health merger agreement was ultimately terminated after the merger was not completed by a specified date. Investors following XAGEW can use these items to understand how the company has sought to align acquisitions and partnerships with its longevity and healthy aging focus.
Regulatory and listing developments also appear in the news flow. The company announced a 1‑for‑30 reverse stock split of its common stock and related adjustments to outstanding warrants, and a Form 25 filed by Nasdaq documents the removal of the company’s common stock and warrants from listing and/or registration on the exchange. For a consolidated view of these events, this news page offers a historical record of Longevity Health Holdings’ press releases and related updates connected to the XAGE and XAGEW securities.
Longevity Health Holdings (NASDAQ:XAGE) has announced a definitive merger agreement with THPlasma in an all-stock transaction valued at $59 million plus $20 million in earnouts. The merger follows Longevity's previous acquisitions of Carmell Therapeutics and Elevai Skincare.
THPlasma, a profitable plasma collection company, is expanding from 2 centers in FY24 to 5 centers in FY25, with guaranteed sales agreements worth $100 million annually. The company projects FY2025 revenue of $10 million and expects significant growth to $32 million in FY2026.
The combined company will continue trading as XAGE, with THPlasma's George Chi becoming Co-Chairman and CEO. Simultaneously, Longevity announced the termination of its planned 20/20 BioLabs transaction. The merger is expected to close in Q4 2025.
Longevity Health Holdings (NASDAQ: XAGE) has successfully completed an at-the-market (ATM) equity offering, selling 479,621 shares at an average price of $4.08 per share, raising gross proceeds of $1.96 million. The funding is expected to extend the company's cash runway into Q1 FY26, based on FY24 pro forma consolidated sales projections. The financing comes as XAGE prepares for its planned merger with 20/20 while continuing to focus on its longevity products business.
Longevity Health Holdings (NASDAQ: XAGE) announced several key business updates. The company has entered into a merger agreement with 20/20 BioLabs on April 11, 2025, with an S-4 prospectus filed on May 8. Q1 unaudited sales showed growth for both companies: XAGE reported $663,000 (+8% YoY) while 20/20 achieved $562,000 (+15% YoY).
The company completed a 1-for-30 reverse stock split on May 12, 2025. Both companies plan Q2 product launches: XAGE will introduce a medicated cleanser for medical professionals, while 20/20 will launch a blood inflammatory biomarker test. Additionally, 20/20 initiated a pilot program with Giant Food for their OneTest™ multi-cancer test at 9 stores in Maryland and Virginia. XAGE is exploring additional financing options for Q2 2025.
Longevity Health Holdings (NASDAQ: XAGE) has announced a 1-for-30 reverse stock split effective May 12, 2025. The split will reduce outstanding shares from approximately 30.1 million to 1 million. Trading on the split-adjusted basis will begin on the Nasdaq Capital Market on May 14, 2025, under the same ticker symbol "XAGE".
The reverse split was approved by stockholders on March 24, 2025. Fractional shares will be rounded up to the nearest whole share. No stockholder action is required for those holding shares electronically or in street name. Proportional adjustments will be made to outstanding stock options, warrants, and shares under the 2023 Equity Incentive Plan.
Longevity Health Holdings (NASDAQ: XAGE) has announced a merger agreement with 20/20 BioLabs in an all-stock transaction valued at approximately $99 million. The merger is expected to double Longevity's fiscal year 2025 revenue from $3-4 million to $7-8 million, with anticipated operational savings of over $1 million.
20/20 BioLabs operates a CLIA Licensed, CAP Accredited lab and offers OneTest™, a multi-cancer early detection blood test for over a dozen tumor types at under $200. The company has integrated its testing into routine evaluations for firefighters and military veterans, and plans to launch a longevity test in Spring 2025.
Post-merger, the combined company will continue trading under XAGE, with Jonathan Cohen appointed as CEO while Rajiv Shukla remains Chairman. The merger advances Longevity's strategy in diagnostics and synergizes with its bio-aesthetic portfolio under the banner "Healthy Aging, Inside and Out™".